Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report available @ Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015
Scope
- The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
A. Menarini Industrie Farmaceutiche Riunite Srl AB Science SA AbbVie Inc. Adamis Pharmaceuticals Corporation Advaxis, Inc. Aeterna Zentaris Inc. Alethia Biotherapeutics Inc. Ambrx, Inc. Amgen Inc. AnGes MG, Inc. Angion Biomedica Corp. Aphios Corporation Armour Therapeutics Inc. Arno Therapeutics, Inc. Arrowhead Research Corporation Astellas Pharma Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc ATLAB Pharma SAS Bavarian Nordic A/S Bayer AG Beta Pharma, Inc. BIND Therapeutics, Inc. Bio-Cancer Treatment International Limited Biscayne Pharmaceuticals, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company CellCentric Ltd Celldex Therapeutics, Inc. Corcept Therapeutics Incorporated CureVac GmbH CytoVac A/S DexTech Medical AB Eisai Co., Ltd. Eli Lilly and Company Emergent BioSolutions Inc. Enceladus Pharmaceuticals BV Endo Pharmaceuticals Inc. EndoCeutics, Inc. Endocyte, Inc. Errant Gene Therapeutics, LLC ESSA Pharma Inc F. Hoffmann-La Roche Ltd. Fujifilm Corporation G1 Therapeutics, Inc. Genentech, Inc. GenSpera, Inc. Glactone Pharma AB GlaxoSmithKline Plc GTx, Inc. Hybrigenics S.A. Immunomedics, Inc. Incuron, LLC Io Therapeutics, Inc. Johnson & Johnson Jyant Technologies, Inc. Karyopharm Therapeutics, Inc. Kura Oncology, Inc. Mediolanum farmaceutici S.p.A. Medivation, Inc. Merck KGaA Millennium Pharmaceuticals, Inc. NewLink Genetics Corporation Novartis AG Oncogenex Pharmaceuticals, Inc. Oncolytics Biotech Inc. Onyx Pharmaceuticals, Inc. Orion Oyj Orphagen Pharmaceuticals, Inc. Panacela Labs, Inc. Pfizer Inc. Progenics Pharmaceuticals, Inc. Sanofi Sotio a.s. Sun Pharma Advanced Research Company Ltd. Supratek Pharma Inc. Synta Pharmaceuticals Corp. Taiho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Tesaro, Inc. Tokai Pharmaceuticals, Inc. TRACON Pharmaceuticals, Inc. Viralytics Ltd.
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report available @ Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015
Scope
- The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
A. Menarini Industrie Farmaceutiche Riunite Srl AB Science SA AbbVie Inc. Adamis Pharmaceuticals Corporation Advaxis, Inc. Aeterna Zentaris Inc. Alethia Biotherapeutics Inc. Ambrx, Inc. Amgen Inc. AnGes MG, Inc. Angion Biomedica Corp. Aphios Corporation Armour Therapeutics Inc. Arno Therapeutics, Inc. Arrowhead Research Corporation Astellas Pharma Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc ATLAB Pharma SAS Bavarian Nordic A/S Bayer AG Beta Pharma, Inc. BIND Therapeutics, Inc. Bio-Cancer Treatment International Limited Biscayne Pharmaceuticals, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company CellCentric Ltd Celldex Therapeutics, Inc. Corcept Therapeutics Incorporated CureVac GmbH CytoVac A/S DexTech Medical AB Eisai Co., Ltd. Eli Lilly and Company Emergent BioSolutions Inc. Enceladus Pharmaceuticals BV Endo Pharmaceuticals Inc. EndoCeutics, Inc. Endocyte, Inc. Errant Gene Therapeutics, LLC ESSA Pharma Inc F. Hoffmann-La Roche Ltd. Fujifilm Corporation G1 Therapeutics, Inc. Genentech, Inc. GenSpera, Inc. Glactone Pharma AB GlaxoSmithKline Plc GTx, Inc. Hybrigenics S.A. Immunomedics, Inc. Incuron, LLC Io Therapeutics, Inc. Johnson & Johnson Jyant Technologies, Inc. Karyopharm Therapeutics, Inc. Kura Oncology, Inc. Mediolanum farmaceutici S.p.A. Medivation, Inc. Merck KGaA Millennium Pharmaceuticals, Inc. NewLink Genetics Corporation Novartis AG Oncogenex Pharmaceuticals, Inc. Oncolytics Biotech Inc. Onyx Pharmaceuticals, Inc. Orion Oyj Orphagen Pharmaceuticals, Inc. Panacela Labs, Inc. Pfizer Inc. Progenics Pharmaceuticals, Inc. Sanofi Sotio a.s. Sun Pharma Advanced Research Company Ltd. Supratek Pharma Inc. Synta Pharmaceuticals Corp. Taiho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Tesaro, Inc. Tokai Pharmaceuticals, Inc. TRACON Pharmaceuticals, Inc. Viralytics Ltd.
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 21:50
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home